ArticleProceedings (Baylor University. Medical Center)2025
Exploring apremilast in the treatment of lichen planus pemphigoides: a new remedy.
Article in Proceedings (Baylor University. Medical Center), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lichen planus pemphigoides (LPP) is an uncommon autoimmune dermatosis characterized by a combination of lichenoid lesions and bullous lesions. While its pathogenesis is often considered idiopathic, some cases have been associated with certain medications and infections. The standard treatment for LPP involves systemic corticosteroids. However, the suboptimal recurrence rate of 20% and the presence of various side effects highlight the need for alternative approaches. Recognizing the role of proinflammatory cytokines in the pathogenesis of LPP and targeting their reduction and related pathways has emerged as a promising therapeutic strategy. This case report details the experience of a 67-year-old woman with a history of LPP, showing disease progression despite undergoing multiple conventional therapies. Faced with the inadequacy of traditional treatments, we achieved successful results by using apremilast as an effective intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.